Kamada (KMDA) Net Equity Issued and Repurchased (2013 - 2023)

Kamada (KMDA) posted quarterly Net Equity Issued and Repurchased of $58.2 million for Q3 2023, up 5823200.0% on a QoQ basis from -$1000.0 in Q3 2020.

Kamada (KMDA) Net Equity Issued and Repurchased (2013 - 2023) Analysis & Trends

Kamada (KMDA) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $58.2 million the latest figure, recorded in Q3 2023.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $58.2 million in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $58.2 million (changed N/A YoY) and the FY2023 annual result came in at $58.2 million, changed N/A from the prior year.
Net Equity Issued and Repurchased rose to $58.2 million in Q3 2023 per KMDA's latest filing, from -$1000.0 in the prior quarter.
Over the last five years, Net Equity Issued and Repurchased for KMDA reached as high as $58.2 million in Q3 2023 and fell as low as -$1000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	500,000.00
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	23.60 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Kamada	401.22 Mn	328.07 Mn	19.12 Mn	-

Download Data